MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company's product candidates include margetuximab, flotetuzumab, and teplizumab. MacroGenics was founded in 2000 and is headquartered in Rockville, Maryland. The company has collaborations with various pharmaceutical companies, including Incyte, Zai Lab, and Janssen Biotech. MacroGenics has approximately 500 employees.